Home About Us Products Clinical Trials News Investors Contact Board of Directors Iain Ross Chairman Iain Ross was appointed to the Board in July 2021. Iain Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years. He held senior commercial roles at Sandoz, Fisons and Hoffman La Roche before moving into the biotechnology sector where he has been C... Read more... Olav Hellebo Chief Executive Officer Olav Hellebø was appointed to the Board in September 2014. Prior to ReNeuron, he held the role of CEO at Clavis Pharma ASA, a Norwegian, oncology-focused, listed biotechnology company. He joined Clavis from UCB where he built the global organisation responsible for the successful registration and launch of the anti-TNF Cimzia... Read more... Catherine Isted ACMA Chief Financial Officer Catherine Isted was appointed to the Board in October 2021. Catherine joined ReNeuron from Oxford Biomedica plc, a global leading cell and gene therapy company, where she was part of the finance leadership team heading up the Corporate Development and IR, helping the business grow over 800%, enter the FTSE250 a... Read more... Barbara Staehelin Senior Independent Non-Executive Director Barbara Staehelin was appointed to the Board on 14 July 2021. Ms. Staehelin’s career in the international life sciences and technology sectors spans over 30 years and includes consulting, CEO and Chair roles. She has led and co-founded four life science companies and is currently on the Board as President of the Audit and Ris... Read more... Dr Tim Corn MSc FFPM FRCPsych Non-Executive Director Dr Tim Corn was appointed to the Board in June 2012. He serves as Chief Medical Officer of both Izana Bioscience and Akasa Bioscience, and is a Trustee of Nerve Tumours UK. He was formerly Chief Medical Officer at EUSA Pharma International, a division of Jazz Pharmaceuticals, at EUSA Pharma Inc and at Zeneus Pharma, as... Read more... Mark Evans Non-Executive Director Mark Evans was appointed to the Board in September 2020. Mark, a science graduate from the University of Bristol, began his career as a graduate trainee at Morgan Grenfell, a British merchant bank. He then worked in emerging markets at ING Bank and Montpelier Asset Management before joining THS Partners in 1998 to manage glob... Read more... Dr Mike Owen Ph.D Non-Executive Director Dr Mike Owen was appointed to the Board in December 2015. He currently serves as a director of Zealand Pharma, Ossianix Inc. Ossianix UK Ltd, GammaDelta Therapeutics Ltd. He is also a member of the scientific advisory board at Avacta Group plc. His career in biotech, the pharmaceutical industry and academia spans almos... Read more... Section: About Us About ReNeuron Board of Directors Senior Management Advisory Board Working at ReNeuron Patents Subscribe here for our Press Releases: The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: I agree Click here © ReNeuron Group plc 2021 All rights reserved Website design by Carr Kamasa Design Privacy Notice Disclaimer